NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., October 19, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=108709&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is November 5, 2024, and participation does not require appointment as a lead plaintiff [2]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEWS ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107867&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107506&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy products, botensilimab and balstilimab, which were overstated [2] - It is alleged that the clinical results and regulatory prospects of these products were misrepresented, leading to materially false and misleading public statements [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require this [2] - Class members may be entitled to compensation without any out-of-pocket costs or fees [2] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [3]

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107034&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=106639&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...